Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
Become a Member | Sign in
Home>News>This Article

Recipharm Contracted by ViroPharma

Published: Thursday, March 15, 2012
Last Updated: Wednesday, March 14, 2012
Bookmark and Share
Commercial contract to initiate supply of Plenadren® for named patient use.

Recipharm has announced that it has been contracted by ViroPharma to complete commercial scale-up manufacture of Plenadren® (Hydrocortisone, Modified Release Tablet) - used for the treatment of adrenal insufficiency in adults.

Under the contractual terms, ViroPharma is also investing in new equipment in order to increase the manufacturing capacity for Plenadren in order to support commercial product launches across Europe.

The new agreement follows the completion of Recipharm’s initial scale-up contract with DuoCort Pharma AB - a recent acquisition for ViroPharma following Plenadren’s® receipt of European Marketing Authorization and Confirmation of Orphan Drug Designation.

Additionally, Recipharm will also be able to use the new equipment for other projects, with ViroPharma retaining its status as highest priority customer.

Helene Fehrm, General Manager of Recipharm Stockholm, said: “We are really pleased ViroPharma has chosen to work together with Recipharm for commercial scale up following the highly successful relationship we had developed with DuoCort. We look forward to building a long term relationship with ViroPharma for its production. This investment and the work we are doing for ViroPharma will give us further valuable experience in tablet manufacturing with API in the coating - a unique advantage over conventional approaches - both for Plenadren® itself and other customers moving forwards.”

Marco Carli, General Manager, Principal & Senior Director, Supply Chain, Europe added: “We are delighted to continue DuoCort’s long-standing relationship with Recipharm as they have been a key component in the development process for Plenadren®, and we look forward to building a long term relationship.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm and LIDDS Sign Contract
Contract for production of Liproca® Depot and investment in LIDDS.
Thursday, December 17, 2015
Recipharm is Commencing Negotiations with LIDDS
Collaboration on large-scale manufacture of Liproca® Depot.
Friday, April 24, 2015
Recipharm Acquires Lusomedicamenta for SEK 1 Billion
Limited customer overlap and significant export activities from Lusomedicamenta, will give Recipharm access to new markets and customers.
Tuesday, November 18, 2014
Recipharm Site in France Approved for Supply to Japan
Recipharm’s solid dose facility in Fontaine, near Dijon in France, has been approved to supply manufactured products to Japan following a recent inspection by the PMDA, the Japanese drug agency.
Tuesday, April 02, 2013
Scientific News
Cutting the Cost of Drug-Building Chemicals
EPFL scientists have developed a method to produce aryl-containing amines in a cheap and easily scalable way.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Pharmacy on Demand
New, portable system can be configured to produce different drugs.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Countless New, Cleaner Uses of Methane
Chemists have demonstrated the potential to use methane as a versatile chemical building block with which to make more complex molecules.
New Way to Control Chemical Reactions
Scientists have harnessed static electricity to control chemical reactions for the first time, in a breakthrough that could bring cleaner industry and cheaper nanotechnology.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos